# Upper Limb Function in Later-Onset SMA

Keywords: SMA, 5q SMA, nusinersen, CHERISH study, upper limb function, RULM, motor milestones, safety profile

> This page provides an overview of the CHERISH study, which evaluated the effectiveness of nusinersen in improving upper limb function in patients with later-onset spinal muscular atrophy (SMA), with a focus on clinical outcomes, motor milestones, and safety data.

## Details

- [Introduction](#): The website focuses on 5q SMA, the most common form of the disease, and discusses its treatment with nusinersen.
- [Upper Limb Function Improvements](#): Patients with later-onset SMA treated with nusinersen showed clinically meaningful improvements in upper limb function compared to sham control, as measured by RULM scores.
- [CHERISH Study Description](#): A Phase III, multicenter, randomized, double-blind, sham-controlled study involving 126 children with later-onset SMA, assessing nusinersen's impact on motor milestones and upper limb function over 15 months.
- [Safety Profile](#): Explore the safety outcomes of nusinersen in treating later-onset Type II SMA, including adverse event reporting guidelines.
- [References](#): Includes citations for clinical data and study methodologies related to nusinersen and SMA treatment.
- [Adverse Event Reporting](#): Provides detailed instructions for reporting adverse events in the UK and Ireland, including contact information for Biogen.